The reporter learned from the Sichuan Provincial Medical Security Bureau that on February 3, the Sichuan Provincial Medical Security Bureau officially announced the first release of deuterium remidevir hydrobromide tablets (trade name: Mindevir) independently declared by Shanghai Wangshi Biomedical Technology Co., Ltd. Quotation, 795 yuan per course of new domestic new crown treatment drugs is expected to quickly enter the Chinese market.
According to reports, on January 6, the Office of the National Medical Insurance Bureau issued the "Guidelines for the Formation of New Coronary Drug Price Formation (Trial)", and the Sichuan Provincial Medical Security Bureau was used as the first price acceptance unit for the new crown drug, and it was the first time to enter the domestic pharmaceutical centralized procurement market. For the treatment of new crowns, centralized acceptance of initial quotations will be implemented, and it will be accepted nationwide.
On January 29, Shanghai Wangshi Biomedical Technology Co., Ltd.’s Class 1 innovative drug Remidevir Hydrobromide Tablets (trade name: Mindevil) and other two oral small-molecule new coronavirus infection treatment drugs were approved by the National Pharmaceutical Co., Ltd. According to the emergency review and approval procedures of special drug approval procedures, the regulatory bureau approved the listing with conditions.
Afterwards, the first quotation application was quickly submitted to the Sichuan Provincial Medical Security Bureau. The Sichuan Provincial Medical Security Bureau accepted the company's application in a timely manner in accordance with the regulations and publicized it as soon as possible.
Chengdu Commercial Daily-Red Star News reporter Wang Tuo